New Hope for Lung Cancer Patients

Monday, 03 Jun 2013 12:44 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

A drug designed to block a protein known to help cancer cells grow was shown in a mid-stage trial to lengthen survival in patients with advanced lung cancer that worsened after initial treatment, researchers said on Monday.
 
The results, presented at a meeting of the American Society of Clinical Oncology in Chicago, are the first time an agent in a class known as heat shock protein 90 inhibitors, HSP90 for short, has been shown to be safe and effective, they said.
 
Ganetespib, developed by Synta Pharmaceuticals, is designed to block HSP90, serving to knock out a pathway used by many different cancer-fueling proteins.
 
The Phase 2 trial, conducted by researchers from the Winship Cancer Institute of Emory University in Atlanta, involved 252 patients with late-stage lung adenocarcinoma, the most common type of lung cancer. It accounts for about 45 percent of the 170,000 non-small cell lung cancer cases diagnosed in the United States each year.
 
The study compared treatment with a combination of ganetespib and chemotherapy to chemotherapy alone. Patients on the drug lived for a median of 9.8 months, compared with 7.4 months for patients given just chemotherapy.
 
For patients whose cancer was diagnosed six months or more before the start of the study, overall survival improved to 10.7 months compared with 6.4 months - a gain of 67 percent.
That group of patients is being studied in a pivotal trial of ganetespib.
 
Side effects associated with the drug included low white blood cell levels, fatigue and diarrhea.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Spacing Between Sibling Births Linked to Autism Risk

Tuesday, 30 Sep 2014 19:13 PM

Children conceived either less than one year or more than five years after the birth of a sibling could be at increased  . . .

Light at Night May Hamper Breast Cancer Treatment: Study

Tuesday, 30 Sep 2014 19:08 PM

A study in rats hints that exposure to dim light at night may make human breast cancer tumors resistant to the chemother . . .

First Ebola Case Diagnosed in US Is 'Critically Ill'

Tuesday, 30 Sep 2014 16:58 PM

The first case of deadly Ebola diagnosed in the U.S. has been confirmed in Dallas, in a man who was traveling in Liberia . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved